ATHE
Alterity Therapeutics LtdNASDAQ
Healthcare • Biotechnology
Updated 1 day ago
Coverage ready
Factor tilt: Anti-Quality Micro Cap
$2.85-2.73%
Close Oct 13, 2026
- Market cap
- $51.66M
- 1 month
- -26.2%
- 3 months
- -42.9%
- 1 year
- -33.6%
- 52-week range
- $2.85$5.89
- Dividend
- No dividends on record
- Short interest
- 0.2% of float26.1K shares · settled Sep 30, 2026 · +1.7% since Sep 15, 2026 · FINRA
End-of-day close from stored market data, not a live quote.
Portfolio context
Sign in to see your position size
We’ll show you if ATHE is in your portfolio and how much it contributes.
Sign inMarket context
Loading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
Smart money context
Holder IQ: MEDIUM
2 top institutions tracked
as of 2026-Q2 (filed 2026-09-02)
Insider context
Sentiment: bullish
Last trade: buy 36 days ago
Red flags: 4
Largest 13-F holders · Q2 2026
22 filers reported a long position in ATHE for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| Twin Lakes Capital Management, LLC | $747.8K | 139.3K | Unchanged |
| MORGAN STANLEY | $338.7K | 63.1K | +8% |
| GREENLEAF TRUST | $332.9K | 62K | +93.8% |
| HB Wealth Management, LLC | $313.9K | 58.5K | Unchanged |
| CITADEL ADVISORS LLC | $201.9K | 37.6K | +87.3% |
| HRT FINANCIAL LP | $92K | 17.3K | New |
| BNP PARIBAS FINANCIAL MARKETS | $55K | 10.2K | +50.4% |
| GAMMA Investing LLC | $12.4K | 2.3K | +24.4% |
| RHUMBLINE ADVISERS | $10.8K | 2K | +2% |
| ACADIAN ASSET MANAGEMENT LLC | $10K | 1.9K | Unchanged |
Get the Full Analysis for ATHE
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.